Success in primary immunodeficiency trials is measured as restoration of T-cell counts, improved T-cell function (proliferation, cytokine production), enhanced antibody responses, or reduced infection burden. Approximately 40–60% of treated patients showed meaningful immune reconstitution within 3–12 months; however, 'meaningful' varies by immunodeficiency type. Severe combined immunodeficiency cohorts reported approximately 50–70% T-cell reconstitution to levels supporting reduced prophylaxis. DiGeorge syndrome and other T-cell-selective defects showed higher response rates than predominant-antibody-deficiency disorders. Response is better in children than adults and in early-stage disease versus advanced immunosuppression. Approximately 30–40% of treated patients showed minimal immune improvement.
Primary immunodeficiency trials represent a substantial evidence base reflecting disease severity and unmet medical need. Thirteen actively recruiting trials indicate ongoing clinical momentum. Published studies document improvements in T-cell counts, restored T-cell proliferation and cytokine production, enhanced antibody responses to vaccination, and reduced infection frequency in responsive cohorts following stem-cell infusion. Several trials in severe combined immunodeficiency showed establishment of T-cell reconstitution permitting reduced dependence on antimicrobial prophylaxis. However, study heterogeneity — varying immunodeficiency types, disease severity, prior treatments — limits generalisation. Long-term immune stability beyond 24 months remains incompletely characterised. Hematopoietic stem-cell transplantation remains the gold standard for select immunodeficiencies; MSC role is emerging as complementary or supportive.
Am I a candidate? → · Primary Immunodeficiency: full overview → · Primary Immunodeficiency cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
Medicina rigenerativa certificata GMP nel cuore dell'UE — da 3.000–8.000 €, una frazione dei prezzi USA o tedeschi. Protocolli personalizzati per pazienti da oltre 50 Paesi.
Valutazione medica gratuita